Fierce JPM Week 2025

The right real-world data can make a difference at every stage of the life sciences product life cycle – from market research and clinical trial design to go-to-market and commercialization strategies. And the right technology should deliver a unified platform experience and single source of truth across the enterprise for high-fidelity patient insights, streamlined operations, aligned decision-making, and improved therapeutic options for patients.

Join Arif Nathoo (CEO and Co-Founder of Komodo Health) and Jorge Santos da Silva (CEO and Co-Founder of MoonLake Immunotherapeutic) for a discussion on how emerging biotechs and life sciences giants alike can harness the power of a unified platform powered by regulatory-grade real-world data to transform business strategy and deliver transformative treatments to patients in need.

Explore practical and flexible approaches to clinical trial partnerships, focusing on risk-sharing models that reduce financial burdens while fostering collaboration and commercial success.

Key Highlights:

• Performance-Based Models: Share financial risks with clear goals and incentives for strategic alignment.
•  Revenue Sharing for Biotech: Support smaller firms and innovative therapies with shared financial burdens and future revenue potential.
•  Hybrid Approaches: Combine milestone-based payments with revenue-sharing elements to balance commitment and flexibility.

Highlighting how AI-driven spatial biomarkers can transform drug development across the entire clinical lifecycle, from discovery to patient stratification and therapy optimization.

The global Pharmacovigilance (PV)/Drug Safety market, valued at $8.5 billion in 2024, is projected to grow to $19.1 billion by 2034, reflecting the increasing importance of safety monitoring in life sciences R&D.  To support this growing trend, recent years have seen the emergence of innovative disruptors, reshaping traditional industry practices with new approaches and technologies.  A major trend in the industry has been the integration of advanced, AI-driven solutions that streamline and enhance PV operations.

In this session, Raj More, Chief Architect & CEO of RxLogix Corporation will discuss how a fully integrated AI-drive digital platform has the potential to expand into Clinical and Regulatory Information Management systems, paving the way for a holistic end-to-end Life Sciences platform. Mr. More will also highlight specific examples of how the RxLogix Safety Platform (RSP) drives substantial positive impacts for both life sciences companies and regulatory Agencies by increasing efficiency and allowing for consolidation and cost savings.

Ginkgo Bioworks optimized its lab footprint through strategic decisions on equipment utilization and space allocation, driving significant operational efficiency. Using a data-driven approach, we achieved measurable reductions in lab space within just six months, aligning with 2024 targets for a leaner, more efficient operation. This case study also highlights broader lessons from Ginkgo’s journey toward operational excellence, showcasing how we adapted to an evolving market landscape, where some companies have faced challenging years. We’ll share insights into how restructuring and scalability efforts have positioned Ginkgo for sustainable growth.